NCT05754177View on ClinicalTrials.gov

Safety and Efficacy of a Probiotic Supplement in IBS-D

NACompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

June 6, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Irritable Bowel Syndrome With DiarrheaIrritable Bowel Syndrome
Interventions
DIETARY_SUPPLEMENT

Probiotic

Participants in this arm will receive a daily dose of 1x10\^10 Colony Forming Unit (CFU) of a single strain probiotic (live bacteria), administered orally by 1 capsule a day, for 84 days

OTHER

Placebo

Participants in this arm will receive an equivalent placebo for 84 days.

Trial Locations (1)

Unknown

Vizera, Ljubljana

All Listed Sponsors
collaborator

Vizera d.o.o.

INDUSTRY

lead

The Archer-Daniels-Midland Company

INDUSTRY

NCT05754177 - Safety and Efficacy of a Probiotic Supplement in IBS-D | Biotech Hunter | Biotech Hunter